Publication:
The association of serum magnesium and mortality outcomes in heart failure patients: A systematic review and meta-analysis

dc.contributor.authorAngkananard T.
dc.contributor.authorAnothaisintawee T.
dc.contributor.authorEursiriwan S.
dc.contributor.authorGorelik O.
dc.contributor.authorMcevoy M.
dc.contributor.authorAttia J.
dc.contributor.authorThakkinstian A.
dc.date.accessioned2021-04-05T03:24:49Z
dc.date.available2021-04-05T03:24:49Z
dc.date.issued2016
dc.date.issuedBE2559
dc.description.abstractBackground: Low serum magnesium (Mg) has been independently shown to increase risk of heart failure (HF), but data on the association between serum Mg concentration and the outcome of patients with HF are conflicting. The purpose of this systematic review and meta-analysis was to estimate the prognostic effects of hypermagnesemia and hypomagnesemia on cardiovascular (CV) mortality and all-cause mortality (ACM) of patients with HF. Methods: Relevant studies were identified from Medline and Scopus databases. Included and excluded criteria were defined. Effects (i.e., log [risk ratio [RR]]) of hypomagnesemia and hypermagnesemia versus normomagnesemia were estimated using Poisson regression, and then a multivariate meta-analysis was applied for pooling RRs across studies. Heterogeneity was explored using a meta-regression and subgroup analysis. Results: On analysis, 7 eligible prospective studies yielded a total of 5172 chronic HF patients with 913 and 1438 deaths from CV and ACM, respectively. Most participants were elderly men with left ventricular (LV) ejection fraction ≤40%. Those patients with baseline hypermagnesemia had a significantly higher risk of CV mortality (RR, 1.38; 95% confidence interval [CI], 1.07-1.78) or ACM (RR, 1.35; 95% CI, 1.18-1.54) than those with baseline normomagnesemia. However, baseline hypomagnesemia was not associated with the risk of CV mortality (RR, 1.11; 95% CI, 0.79-1.57) and ACM (RR, 1.11; 95% CI, 0.87-1.41). A subgroup analysis by Mg cutoff suggested a dose-response trend for hypermagnesemia effects, that is, the pooled RRs for CV mortality were 1.28 (95% CI, 1.05-1.55) and 1.92 (95% CI, 1.00-3.68) for the cutoff of 0.89 to 1.00 and 1.05 to 1.70 mmol/L, respectively. Conclusion: The present systematic review and meta-analysis suggested that, in HF patients, hypermagnesemia with serum Mg=1.05mmol/L was associated with an increased risk of CV mortality and ACM but this was not observed for hypomagnesemia. This finding was limited to the elderly patients with chronic HF who had reduced LV systolic function. © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.
dc.format.mimetypeapplication/pdf
dc.identifier.citationMedicine (United States). Vol 95, No.50 (2016)
dc.identifier.doi10.1097/MD.0000000000005406
dc.identifier.issn257974
dc.identifier.other2-s2.0-85007508449
dc.identifier.urihttps://hdl.handle.net/20.500.14740/5978
dc.rights.holderมหาวิทยาลัยศรีนครินทรวิโรฒ
dc.subject.otherMagnesium
dc.subject.otherBiological marker
dc.subject.otherMagnesium
dc.subject.otherDiuretic agent
dc.subject.otherCardiovascular mortality
dc.subject.otherCerebrovascular accident
dc.subject.otherHeart ejection fraction
dc.subject.otherHeart failure
dc.subject.otherHeart infarction
dc.subject.otherHuman
dc.subject.otherHypermagnesemia
dc.subject.otherHypomagnesemia
dc.subject.otherIschemic heart disease
dc.subject.otherMagnesium blood level
dc.subject.otherMeta analysis
dc.subject.otherOutcome assessment
dc.subject.otherPriority journal
dc.subject.otherPrognosis
dc.subject.otherRandomized controlled trial (topic)
dc.subject.otherReview
dc.subject.otherSudden death
dc.subject.otherSystematic review
dc.subject.otherAge
dc.subject.otherAged
dc.subject.otherBlood
dc.subject.otherCause of death
dc.subject.otherDisease course
dc.subject.otherFemale
dc.subject.otherHeart failure
dc.subject.otherMale
dc.subject.otherMiddle aged
dc.subject.otherMortality
dc.subject.otherPathophysiology
dc.subject.otherProspective study
dc.subject.otherSeverity of illness index
dc.subject.otherSex difference
dc.subject.otherSurvival analysis
dc.subject.otherVery elderly
dc.subject.otherAll cause mortality
dc.subject.otherCardiovascular risk
dc.subject.otherCause of death
dc.subject.otherDisease association
dc.subject.otherDose response
dc.subject.otherHeart left ventricle ejection fraction
dc.subject.otherHigh risk patient
dc.subject.otherHypermagnesemia
dc.subject.otherHypomagnesemia
dc.subject.otherMedline
dc.subject.otherMortality rate
dc.subject.otherRisk assessment
dc.subject.otherRisk factor
dc.subject.otherScopus
dc.subject.otherAge Factors
dc.subject.otherAged
dc.subject.otherAged, 80 and over
dc.subject.otherBiomarkers
dc.subject.otherCause of Death
dc.subject.otherDisease Progression
dc.subject.otherFemale
dc.subject.otherHeart Failure
dc.subject.otherHumans
dc.subject.otherMagnesium
dc.subject.otherMale
dc.subject.otherMiddle Aged
dc.subject.otherProspective Studies
dc.subject.otherSeverity of Illness Index
dc.subject.otherSex Factors
dc.subject.otherSurvival Analysis
dc.titleThe association of serum magnesium and mortality outcomes in heart failure patients: A systematic review and meta-analysis
dc.typeReview
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85007508449&doi=10.1097%2fMD.0000000000005406&partnerID=40&md5=a47e722fd613241ae084816d567a4ddd

Files